AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00003364
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003364
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03847727
Drug: BR as Maintenance
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients of the study group who have achieved at least a partial response after 6 cycles of BR induction will receive additionally 4 cycles of BR every 3 months as maintenance therapy.
Trial: NCT02216084
Drug: Recombinant ADAMTS13
RxNorm normalized name: ADAMTS13, recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.~Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3).
Trial: NCT01209078
Drug: GSK1322322
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1322322 1500mg BID
Trial: NCT01209078
Drug: GSK1322322 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03070899
Drug: OBE2109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBE2109 100mg tablets for oral administration once daily
Trial: NCT03070899
Drug: Placebo to match OBE2109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match OBE2109 100mg tablets for oral administration once daily
Trial: NCT03070899
Drug: Placebo to match Add-back
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Trial: NCT01266590
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02782260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01170637
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg oral administration (RhinAdvil(R))
Trial: NCT01170637
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg oral administration (BI product)
Trial: NCT01968356
Drug: 3M CHG/IPA Prep Colorless
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically.
Trial: NCT01601457
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
Trial: NCT02253966
Drug: Methylprednisoloneacetate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03676114
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same volume of normal saline will be administrated
Trial: NCT03842839
Drug: Salbutamol sulphate aerosol (Ventolin) 0.01mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens
Trial: NCT01240980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, Oral, 0 mg, once daily, 1 day
Trial: NCT01240980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension, Oral, 0 mg, once daily, 1 day
Trial: NCT01240980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension using crystalline form, Oral, 0 mg, once daily, 1 day
Trial: NCT02347891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized phase: Week 0 - Week 40
Trial: NCT00538044
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
Trial: NCT00070135
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02947438
Drug: EPREX®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Trial: NCT02947438
Drug: EPIAO®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Trial: NCT04318158
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
Trial: NCT00878969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02056106
Drug: antidepressant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00524914
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo subcutaneous
Trial: NCT01592162
Drug: propofol 1% (Astra-Zeneca) and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
Trial: NCT01592162
Drug: propofol 1% (Astra-Zeneca) and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
Trial: NCT01592162
Drug: Propofol (Astra-Zeneca) and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
Trial: NCT01592162
Drug: Propofol (Astra-Zeneca) and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
Trial: NCT01592162
Drug: Propofol (B-Braun) and remifentanil
RxNorm normalized name: DISPENSING PIN B BRAUN #415072
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
Trial: NCT03373058
Drug: adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group.
Trial: NCT01722097
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01896609
Drug: Bon one in Arm 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks
Trial: NCT01896609
Drug: Xerovirinc in Arm 2
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks
Trial: NCT02946814
Drug: essential oils
RxNorm normalized name: essential oils
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00651599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
Trial: NCT03207906
Drug: VBP-926
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical VBP-926 solution
Trial: NCT03441607
Drug: mHACMb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ingredient
Trial: NCT03404726
Drug: BAY2402234
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY2402234 is a potent and selective small molecule inhibitor of dihydroorotate dehydrogenase. A solution of BAY2402234 will be available to initiate the trial and there are plans to transition to a tablet form of BAY2402234 once it becomes available. Both liquid and tablet formulations of BAY2402234 will be continually administered once daily by mouth in 28 day cycles.
Trial: NCT03188068
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administered with sirolimus
Trial: NCT04281901
Drug: Platelet- and extracellular vesicle-rich plasma
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ear wick soaked in platelet- and extracellular vesicle-rich plasma
Trial: NCT04281901
Drug: Standard conservative treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard conservative measures, including antimicrobials, antiseptics and aural toilette for treating a chronically inflamed radical cavity.
Trial: NCT03495739
Drug: RDG-17012 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran Etexilate tosylate 150mg
Trial: NCT02971475
Drug: Analgesics
RxNorm normalized name: ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
Trial: NCT03363451
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observation study, no specific antibiotics will be indicated during treatment
Trial: NCT02285543
Drug: TPF induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy
Trial: NCT00003884
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00004400
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04017832
Drug: Placebo (oral semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet to be taken first thing in the morning
Trial: NCT04017832
Drug: Placebo (sitagliptin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet to be taken 30 minutes after oral semaglutide
Trial: NCT02203656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo supplement
Trial: NCT02930473
Drug: Psychopharmaceuticals (any drugs prescribed by the psychiatrist)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.
Trial: NCT00005046
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02203656
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone injection
Trial: NCT04584736
Drug: Livalo, Ezetrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin+Ezetimibe Pitavastatin
Trial: NCT02938286
Drug: AHES
RxNorm normalized name: STOMAHESIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application at test region I-IV under occlusion for 15 minutes
Trial: NCT04127513
Drug: Urea
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% urea moisturizing cream
Trial: NCT02255318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02344290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet taken once daily, orally with or without food
Trial: NCT00865917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching appearance
Trial: NCT02792114
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02792114
Drug: AP1903
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03005223
Drug: Co-administration of DWC20155/DWC20156
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03005223
Drug: DWC20163
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04450407
Drug: LY3209590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03061656
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1st HDCT
Trial: NCT02548351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04054973
Drug: Sapropterin Dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 800mg of Kuvan daily for 14 days
Trial: NCT00110032
Drug: EF5
RxNorm normalized name: Hb 76(EF5), Met-thr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00927966
Drug: CP-751,871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously on Day 1 of a 21-day cycle
Trial: NCT04284930
Drug: OnQ pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.
Trial: NCT02101931
Drug: Amino levulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The bladder cancer patients is required to swallow a chemical called Amino levulinic Acid, about 10mg/kg body weight. 5ml of blood and one urine samples will be taken before using Amino levulinic Acid. The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking ALA and the samples will be analyzed by photodynamic diagnostic procedure. ALA gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).
Trial: NCT04092673
Drug: eFT226
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).
Trial: NCT01618474
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
Trial: NCT04781361
Drug: Intravenous isotonic fluid - NaCl 131-154 mmol/L in 5% dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic group will be given fluids containing 131-154 mmol/L Sodium Chloride
Trial: NCT02244164
Drug: Incretinomimetics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04618601
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to the high-dose spironolactone group will receive oral spironolactone (≥100 mg) on top of standard of care treatment for acute heart failure immediately after randomization and in the afternoon of each subsequent day unless the serum potassium level is \>5 mmol/L. The exact dose will be determined based on a pre-specified algorithm provided.
Trial: NCT03784040
Drug: OTSGC-A24
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
Trial: NCT03128320
Drug: BAY1193397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1 mg BAY1193397 given in the fasted state
Trial: NCT03128320
Drug: BAY1193397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 5 mg BAY1193397 given in the fasted state
Trial: NCT03128320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo given in the fasted state
Trial: NCT04483492
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: diaphragm contractility after administration
Trial: NCT02188472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 2 tablets should be taken twice daily
Trial: NCT02089334
Drug: RX-0201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RX-0201 will be administered in a dose up to 250mg/m\^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.~In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles.
Trial: NCT00792376
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
Trial: NCT00792376
Drug: diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
Trial: NCT01862939
Drug: DS-7309
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.
Trial: NCT01862939
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match part 2 DS-7309
Trial: NCT01188876
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally on a daily basis starting 7 days before the first dose of pralatrexate and continuing until 30 days after the last dose of pralatrexate.
Trial: NCT03245385
Drug: Treatment with Halobetasol propionate 0.05% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with topical halobetasol 0.05% spray applied twice daily for 14 days. Patients will be instructed not to rub over the affected area after application of spray. Each patient is expected to receive 28 doses. The maximum amount of test product applied per week will not exceed 50 g
Trial: NCT00722501
Drug: ERB-257
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03140072
Drug: AZD9898
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of AZD9898, under fasted conditions. Starting dose in part 1 (SAD in healthy subjects) is 3 mg, subsequent doses will be selected based on emerging data. In Part 3 of the study, each subject will receive one dose level of AZD9898, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
Trial: NCT03140072
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of matching placebo, under fasted conditions. In Part 3 of the study, each subject will receive one dose level of matching placebo, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
Trial: NCT04417972
Drug: SHR7280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment
Trial: NCT04417972
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blank control
Trial: NCT02211963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05303324
Drug: ALXN1840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received ALXN1840 at Hour 0 on Day 1 of the dosing period.
Trial: NCT00656487
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo